Cannamore Biotechs Overview
CannaMore is a preclinical- and clinical-stage research platform company committed to the development of novel and improved cannabis-based treatment options that will potentially benefit millions of patients worldwide. The company is focusing on the development of a CBD-based solution for the treatment of bronchiolitis obliterans, peripheral neuropathy, and inflammatory bowel diseases. CannaMore is a portfolio company of BioSeedXL.
Latest News
N/A
Driving medical cannabis-based therapies forward with biotech
The article features an interview with David Bassa, a biotech entrepreneur, discussing his background, track record, and current projects in the biotech field. Bassa is leading three CBD-based pharmaceutical companies and working on solutions for various diseases. He emphasizes the importance of digital healthcare and the potential of medical cannabis in providing safe and regulated treatments. Bassa calls for the support of large pharmaceutical companies to further develop and acquire his solutions. The article highlights the success of GW Pharmaceuticals in developing a CBD solution for childhood epilepsy, which sold for $7 billion. Bassa expresses the need for collaboration and clinical trials to establish his solutions as established medicines.
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | Undisclosed |
| Last funding | Undisclosed |
| Stage | Pre-Funding |
| Rounds | 0 |
| Investors | 0 |
Team Members
7
Employees: 1-10
Web & Social Links
| Website | cannamorebio.com |
Locations
Barukh Hirsch St 18, Bnei Brak, Israel
Photos & Videos
No files yet
